Serum Institute confirms AstraZeneca's safety, says trials progressing smoothly
- Serum Institute of India said the Indian trials are progressing smoothly
- AstraZeneca and Oxford University have acknowledged a manufacturing error
- It has raised questions about preliminary results of their experimental COVID-19 vaccine
The COVID-19 vaccine developed by AstraZeneca and Oxford University is safe and effective, said the Serum Institute of India on Thursday, adding that the Indian trials are progressing smoothly with strict adherence to all protocols, reported PTI.
The comments come in view of AstraZeneca and Oxford University acknowledging a manufacturing error, which has raised questions about preliminary results of their experimental COVID-19 vaccine.
Days after the company and the university described the shots as "highly effective", a statement describing the error came. There is yet no information on why some study participants did not receive as much vaccine in the first of two shots as expected.
In a statement, the Serum Institute of India (SII) said, "The AstraZeneca-Oxford vaccine is safe and effective. Even the lowest efficacy results are at 60-70%, making it a viable vaccine against the virus. We must be patient and not panic."
Clinical trials of AstraZeneca-Oxford's COVID-19 vaccine candidate in India is being conducted by SII. It said, "The Indian trials are running smoothly with strict adherence to all the necessary processes and protocols. So far, there are no concerns. However, we are going through the data that is available and will make further statement, if needed."
According to AstraZeneca, an interim analysis of clinical trials of its COVID-19 vaccine in the UK and Brazil showed that it was 70% effective on average, becoming the third drugmaker to announce promising results to contain the deadly virus.
The company had also said that the vaccine, developed with the University of Oxford, showed 90% efficacy in one dosing regimen when the vaccine was given as a half dose, followed by a full dose at least a month later, while another dosing regimen showed 62# efficacy when given as two full doses at least one month apart.
It had said, "The combined analysis from both dosing regimens resulted in an average efficacy of 70%."